Pronova BioPharma ASA : Offer Document from BASF Approved by the Oslo Stock Exchange

12/5/2012, 8:58 AM (Source: GlobeNewswire)


· The Offer Document from BASF has been approved by the Oslo Stock Exchange
· The Offer has been unanimously recommended by Pronova BioPharma's Board of Directors
· Irrevocable pre-acceptances from shareholders representing approximately 60%
· Offer period from and including 5 December to 19 December
· Offer document, including full details about the offer, is made available today

Lysaker, Norway - 5 December 2012: Reference is made to the stock exchange notice from Pronova BioPharma ASA ("Pronova" or the "Company") of 21 November 2012 regarding the transaction agreement with BASF SE ("BASF"), whereby BASF committed to make a voluntary offer to acquire all outstanding shares of Pronova for NOK 12.50 per share in cash (the "Offer").
The offer document with the detailed terms and conditions of the Offer (the "Offer Document") has been reviewed and approved by the Oslo Stock Exchange in accordance with Section 6-14 of the Norwegian Securities Trading Act.

The offer period is from and including 5 December 2012 to and including 19 December 2012 at 09.00 (CET). Herkules Private Equity, Kistefos, Pronova's Directors and Management, in aggregate representing approximately 60% of the Company's share capital and votes, have irrevocably undertaken to accept the Offer. These pre-acceptances cannot be withdrawn in the event of a competing offer.

Pronova's Board of Directors has unanimously recommended that shareholders accept the offer.

The Offer Document will, subject to restrictions under applicable securities laws, be available at the commencement of the offer period at the website of receiving agent Arctic Securities ( The Offer Document will also be available at the website of Pronova ( The Offer Document will, subject to restrictions under applicable securities laws, also be sent to the shareholders of Pronova.

The offer and the distribution of this announcement and other information in connection with the offer may be restricted by law in certain jurisdictions.

Pronova has engaged Morgan Stanley & Co. Limited ("Morgan Stanley") as its exclusive financial advisor. ABG Sundal Collier Norge ("ABGSC") has provided an independent statement regarding the Offer in accordance with section 6-16 (1) c.f. 6-19 (1) of the Norwegian Securities Trading Act which is included in the Offer Document.
Contact details
Gert Munthe, Chairman of the Board of Directors,    + 47 92 02 23 63
Morten Jurs, Chief Executive Officer,      +47 99 16 79 22
Synne H. Røine, Chief Financial Officer,     +47 99 22 98 92
Hamed Brodersen, VP Investor Relations and Communications,  +47 40 46 81 10

About Pronova
Pronova is a global leader in research, development and manufacture of lipid therapies derived from nature.

The group's first commercialised product, Omacor/Lovaza, is branded in a number of countries (60) throughout Europe, Asia and in the USA. End-user sales has grown rapidly in all international markets and the annual run rate at 31 December 2011 reached USD 1 380 million, according to IMS Health. The product is the first EU- and FDA-approved omega 3-derived prescription drug. Marketing and distribution of Pronova's key product is currently licensed to both local and global pharmaceutical companies.

The company is in the process of developing several new, patentable lipid derivatives. The most advanced lipid derived pharmaceutical programme is in the area of combined dyslipidemia, the abnormal concentration of lipids and lipoproteins in the blood, for which the company has a product, PRC-4016, in clinical trials.

Pronova has also entered the consumer healthcare market and is developing a clinical nutrition offering, enabling the company to further leverage its position as the world's largest manufacturer of high grade omega-3 derived products.

Pronova's headquarters are located at Lysaker in Norway, while production takes place at state-of-the-art manufacturing facilities at Sandefjord in Norway and in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the ticker code PRON. Additional information is available on

Important Notice
Morgan Stanley & Co. Limited is acting as financial adviser to Pronova and no one else in connection with the matters described in this announcement. In connection with such matters, Morgan Stanley & Co. Limited, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein.


This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Pronova BioPharma ASA via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.